PL3164113T3 - Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych - Google Patents

Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych

Info

Publication number
PL3164113T3
PL3164113T3 PL15753219T PL15753219T PL3164113T3 PL 3164113 T3 PL3164113 T3 PL 3164113T3 PL 15753219 T PL15753219 T PL 15753219T PL 15753219 T PL15753219 T PL 15753219T PL 3164113 T3 PL3164113 T3 PL 3164113T3
Authority
PL
Poland
Prior art keywords
prophylactic
nucleic acids
therapeutic applications
immune modulators
spherical nucleic
Prior art date
Application number
PL15753219T
Other languages
English (en)
Inventor
Aleksandar Filip Radovic-Moreno
Richard Kang
Subbarao NALLAGATLA
Christopher C. Mader
Sergei Gryaznov
Original Assignee
Exicure, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exicure, Inc. filed Critical Exicure, Inc.
Publication of PL3164113T3 publication Critical patent/PL3164113T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
PL15753219T 2014-06-04 2015-06-04 Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych PL3164113T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007528P 2014-06-04 2014-06-04
PCT/US2015/034226 WO2015187966A1 (en) 2014-06-04 2015-06-04 Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP15753219.3A EP3164113B1 (en) 2014-06-04 2015-06-04 Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications

Publications (1)

Publication Number Publication Date
PL3164113T3 true PL3164113T3 (pl) 2019-09-30

Family

ID=53887176

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15753219T PL3164113T3 (pl) 2014-06-04 2015-06-04 Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych

Country Status (11)

Country Link
US (2) US10434064B2 (pl)
EP (2) EP3164113B1 (pl)
JP (1) JP6581604B2 (pl)
KR (1) KR102290205B1 (pl)
CN (1) CN106535876B (pl)
AU (1) AU2015269412B2 (pl)
CA (1) CA2953216C (pl)
ES (1) ES2725948T3 (pl)
PL (1) PL3164113T3 (pl)
TR (1) TR201908550T4 (pl)
WO (1) WO2015187966A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015023797A1 (en) 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
MX2016007287A (es) 2013-12-03 2017-05-03 Univ Northwestern Particulas liposomales, metodos para elaborarlas y sus usos.
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
PE20170694A1 (es) 2014-10-06 2017-05-26 Exicure Inc Compuestos anti-tnf
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10517924B2 (en) 2014-11-24 2019-12-31 Northwestern University High density lipoprotein nanoparticles for inflammation
WO2016115320A1 (en) 2015-01-14 2016-07-21 Exicure, Inc. Nucleic acid nanostructructures with core motifs
US20180042848A1 (en) * 2015-02-18 2018-02-15 Exicure, Inc. Immuno-regulatory lipid containing spherical nucleic acids
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
US20200297867A1 (en) * 2016-02-01 2020-09-24 Exicure, Inc. Surface functionalization of liposomes and liposomal spherical nucleic acids (snas)
WO2017193084A1 (en) * 2016-05-06 2017-11-09 Exicure, Inc. Tlr9-targeted spherical nucleic acids having potent antitumor activity
JP7186094B2 (ja) 2016-05-06 2022-12-08 イグジキュア オペレーティング カンパニー インターロイキン１７受容体ｍＲＮＡの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド（ＡＳＯ）を提示するリポソーム系球状核酸（ＳＮＡ）構築物
WO2017193081A1 (en) * 2016-05-06 2017-11-09 Exicure, Inc. Spherical nucleic acid tlr9 agonists
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
MA49023A (fr) * 2017-03-29 2020-02-05 Inst Basic Medical Sciences Cams Application d'un composé ou d'un extrait de médecine chinoise traditionnelle dans la préparation d'un agent d'administration d'acide nucléique et produits apparentés correspondants
WO2019184991A1 (zh) * 2018-03-29 2019-10-03 中国医学科学院基础医学研究所 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
MX2020000387A (es) 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
ES2960535T3 (es) * 2017-11-02 2024-03-05 Janssen Pharmaceuticals Inc Constructos de oligonucleótidos y usos de los mismos
US20200384104A1 (en) * 2017-12-15 2020-12-10 Northwestern University Structure-Function Relationships in the Development of Immunotherapeutic Agents
EP3923957A4 (en) * 2019-02-12 2022-11-02 Exicure Operating Company COMBINED SPHERICAL NUCLEIC ACID AND CHECKPOINT INHIBITOR FOR ANTITUMORS THERAPY
CN110559263B (zh) * 2019-10-10 2021-05-14 中国海洋大学 一种△5-胆甾硫酸基类化合物脂质体及其制备方法
US20210220454A1 (en) * 2020-01-22 2021-07-22 Northwestern University Design of immunostimulatory protein-core spherical nucleic acids
US20220288181A1 (en) * 2021-03-12 2022-09-15 Northwestern University Antiviral vaccines using spherical nucleic acids

Family Cites Families (301)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5194599A (en) 1988-09-23 1993-03-16 Gilead Sciences, Inc. Hydrogen phosphonodithioate compositions
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5955589A (en) 1991-12-24 1999-09-21 Isis Pharmaceuticals Inc. Gapped 2' modified oligonucleotides
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
FR2677272B1 (fr) 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
US5814666A (en) 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
JPH11504926A (ja) 1995-05-04 1999-05-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド複合体
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
AU3379597A (en) 1996-06-19 1998-01-07 Hybridon, Inc. Modulation of tetraplex formation by chemical modifications of a g4-containing oligonucleotide
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6361944B1 (en) 1996-07-29 2002-03-26 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
EP0856579A1 (en) 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH An antisense oligonucleotide preparation method
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20030104044A1 (en) 1997-05-14 2003-06-05 Semple Sean C. Compositions for stimulating cytokine secretion and inducing an immune response
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US6271209B1 (en) 1998-04-03 2001-08-07 Valentis, Inc. Cationic lipid formulation delivering nucleic acid to peritoneal tumors
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
PT1733735T (pt) 1998-05-22 2017-06-16 Ottawa Hospital Res Inst Métodos e produtos para induzir imunidade mucosal
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
FR2783170B1 (fr) 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6194328B1 (en) 1998-12-09 2001-02-27 Advanced Micro Devices, Inc. H2 diffusion barrier formation by nitrogen incorporation in oxide layer
JP2003503699A (ja) 1999-06-25 2003-01-28 ナノスフェアー インコーポレイテッド オリゴヌクレオチドが付着しているナノ粒子およびその利用法
AU6080500A (en) 1999-07-08 2001-01-30 Cap Biotechnology, Inc. Calcium-containing structures and methods of making and using the same
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
CA2380947C (en) 1999-08-19 2011-11-01 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
EP1221955B9 (en) 1999-09-25 2005-11-30 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US6585947B1 (en) 1999-10-22 2003-07-01 The Board Of Trustess Of The University Of Illinois Method for producing silicon nanoparticles
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
ATE393221T1 (de) 1999-11-29 2008-05-15 Avi Biopharma Inc Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen
WO2001051665A2 (en) 2000-01-13 2001-07-19 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US6534062B2 (en) 2000-03-28 2003-03-18 The Regents Of The University Of California Methods for increasing a cytotoxic T lymphocyte response in vivo
EP1301625B1 (en) 2000-03-28 2010-11-03 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
EP1322656B1 (en) 2000-09-26 2008-01-16 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US7083958B2 (en) 2000-11-20 2006-08-01 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
WO2002069369A2 (en) 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
DE10065475A1 (de) 2000-12-28 2002-07-18 Switch Biotech Ag Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US7176296B2 (en) 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
GB0111279D0 (en) 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
WO2002096262A2 (en) 2001-05-25 2002-12-05 Northwestern University Non-alloying core shell nanoparticles
AU2002314855B2 (en) 2001-05-30 2007-08-09 Board Of Trustees Of The Leland Stanford, Jr., University Delivery system for nucleic acids
ES2421532T3 (es) 2001-06-21 2013-09-03 Dynavax Tech Corp Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos
US7332586B2 (en) 2001-07-10 2008-02-19 North Carolina State University Nanoparticle delivery vehicle
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
CA2456328C (en) 2001-08-07 2015-05-26 Dynavax Technologies Corporation Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
CN1599623B (zh) 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CA2494911A1 (en) 2002-08-12 2004-02-19 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
GB0227738D0 (en) 2002-11-28 2003-01-08 Univ Liverpool Nanoparticle conjugates and method of production thereof
ATE442376T1 (de) 2002-12-23 2009-09-15 Dynavax Tech Corp Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
EP1578419A4 (en) 2002-12-30 2008-11-12 3M Innovative Properties Co IMMUNOSTIMULATING COMBINATIONS
US20060105343A1 (en) 2003-01-09 2006-05-18 Children's Medical Center Corporation Methods for diagnosis and prognosis of cancer
US7851453B2 (en) 2003-01-16 2010-12-14 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7354907B2 (en) 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
WO2004103301A2 (en) 2003-05-16 2004-12-02 Hybridon, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
EP1631576A4 (en) 2003-06-11 2010-08-25 Idera Pharmaceuticals Inc STABILIZED IMMUNOMODULATION OLIGONUCLEOTIDES
US20050096263A1 (en) 2003-10-30 2005-05-05 Keay Susan K. Novel antiproliferative factor and methods of use
ATE494910T1 (de) 2003-07-10 2011-01-15 Cytos Biotechnology Ag Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
WO2005009355A2 (en) 2003-07-15 2005-02-03 Hybridon, Inc. Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
AU2004275876B2 (en) 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
EP1699814A4 (en) 2003-12-08 2009-01-14 Hybridon Inc MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF COMPOUNDS FORMED FROM SMALL OLIGONUCLEOTIDES
US7846412B2 (en) 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
DK1716234T3 (da) 2004-02-20 2014-01-20 Mologen Ag Substitueret, ikke-kodende nukleinsyremolekyle til terapeutisk og profylaktisk immunstimulering i mennesker og højerestående dyr
AU2005217347A1 (en) 2004-02-26 2005-09-09 Layerlab Aktiebolag Oligonucleotides related to lipid membrane attachments
JP2007531746A (ja) 2004-04-02 2007-11-08 コーリー ファーマシューティカル グループ，インコーポレイテッド Ｉｌ−１０応答を誘導するための免疫活性化核酸
US20080274454A1 (en) 2004-04-07 2008-11-06 Mirkin Chad A Reversible and Chemically Programmable Micelle Assembly With Dna Block-Copolymer Amphiphiles
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
EP1604669A1 (en) 2004-06-10 2005-12-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of ATP analogues for treatment of cardiovascular diseases
US7498425B2 (en) 2004-06-15 2009-03-03 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
NZ552522A (en) 2004-06-15 2009-04-30 Idera Pharmaceuticals Inc Immunostimulatory oligonucleotide multimers
KR20070043795A (ko) 2004-07-20 2007-04-25 쉐링 코포레이션 톨-유사 수용체 발현 종양 세포에서 세포자멸사의 유도방법
WO2006012695A1 (en) 2004-08-04 2006-02-09 Panvax Limited An immunogenic composition
WO2006015560A1 (de) 2004-08-09 2006-02-16 Mologen Ag Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen
WO2006044660A2 (en) 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
KR100721928B1 (ko) 2004-11-05 2007-05-28 주식회사 바이오씨에스 ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
US20060135459A1 (en) 2004-11-09 2006-06-22 Epstein Alan L Targeted innate immunity
EP1829887B1 (en) 2004-11-29 2011-08-24 Changchun Huapu Biotechnology Co., Ltd. Cpg single-strand deoxynucleotides for use as adjuvant
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
EP1922300A2 (en) 2005-02-14 2008-05-21 Sirna Therapeutics Inc. Cationic lipids and formulated molecular compositions containing them
US7718622B2 (en) 2005-03-04 2010-05-18 Dynavax Technologies Corporation Compositions comprising structurally stable conjugate molecules
EP1888510A4 (en) 2005-05-27 2013-01-16 Univ North Carolina NITROGEN OXIDE-RELATED PARTICLES FOR NITROGEN OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
KR20080030656A (ko) 2005-07-07 2008-04-04 콜레이 파마시티컬 그룹, 인코포레이티드 암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US20070093439A1 (en) 2005-10-25 2007-04-26 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
FR2892819B1 (fr) 2005-10-28 2008-02-01 Centre Nat Rech Scient Nanoparticules a luminescence persistance pour leur utilisation en tant qu'agent de diagnostic destine a l'imagerie optique in vivo
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP2402442B1 (en) 2005-11-07 2013-07-31 Idera Pharmaceuticals Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7776834B2 (en) 2005-11-07 2010-08-17 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
JP2009514525A (ja) 2005-11-07 2009-04-09 イデラ ファーマシューティカルズ インコーポレイテッド 修飾された免疫刺激性ジヌクレオチドを含む、オリゴヌクレオチドに基づく化合物の免疫刺激特性
PL1957044T3 (pl) 2005-12-01 2013-11-29 Pronai Therapeutics Inc Amfoteryczny preparat liposomowy
AU2006321287B2 (en) 2005-12-01 2013-05-09 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Compositions and methods relating to treatment of cancer and infectious diseases
US20090317802A1 (en) 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
JP5484732B2 (ja) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー 過敏症の治療のための免疫賦活性核酸パッケージ粒子
JP2009521218A (ja) 2005-12-20 2009-06-04 イデラ ファーマシューティカルズ インコーポレイテッド 異なる長さのパリンドロームセグメントを含むパリンドローム免疫調節オリゴヌクレオチド（ｉｍｏ（ｔｍ））の免疫賦活作用
MX2008008278A (es) 2005-12-20 2008-10-01 Idera Pharmaceuticals Inc Agonistas sinteticos novedosos de receptores tipo toll que contienen modificaciones de dinucleotido cg.
US20070148251A1 (en) 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices
AU2006326870A1 (en) 2005-12-22 2007-06-28 Apollo Life Sciences Transdermal delivery of pharmaceutical agents
CA2636424A1 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
WO2007089607A2 (en) 2006-01-26 2007-08-09 University Of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
US7723045B2 (en) 2006-02-10 2010-05-25 The Regents Of The University Of California Assays to predict atherosclerosis and dysfunctional high-density lipoprotein
PT2405002E (pt) 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Composições e métodos para formulações de oligonucleotídeos
EP1820804A1 (en) 2006-02-20 2007-08-22 Humboldt-Universität zu Berlin Lipidated oligonucleotides
WO2007106683A2 (en) 2006-03-10 2007-09-20 The Trustees Of The University Of Pennsylvania Biomimetic iron-oxide-containing lipoprotein and related materials
JP5507998B2 (ja) 2006-05-11 2014-05-28 モロゲン・アーゲー 免疫刺激のための多量体
US20110052697A1 (en) 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
WO2008097328A2 (en) 2006-06-23 2008-08-14 Northwestern University Asymmetric functionalized nanoparticles and methods of use
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
EP2046954A2 (en) * 2006-07-31 2009-04-15 Curevac GmbH NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
US20080124366A1 (en) 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
AU2007286203B2 (en) 2006-08-08 2013-05-02 Board Of Regents, The University Of Texas System Multistage delivery of active agents
LT2484375T (lt) 2006-09-26 2018-07-10 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
US7884197B2 (en) 2006-12-12 2011-02-08 Idera Pharmaceuticals, Inc. Synthetic agonists of TLR9
US20080181928A1 (en) 2006-12-22 2008-07-31 Miv Therapeutics, Inc. Coatings for implantable medical devices for liposome delivery
WO2008089248A2 (en) 2007-01-19 2008-07-24 The Board Of Trustees Of The University Of Illinois Amphiphilic substances and triggered liberation from lipid vesicles
US20100144848A1 (en) 2007-01-24 2010-06-10 Syddansk Universitet Dna controlled assembly of lipid membranes
MX2009008470A (es) 2007-02-09 2009-11-26 Univ Northwestern Particulas para detectar objetivos intracelulares.
US20100167290A1 (en) 2007-02-27 2010-07-01 Robert Elghanian Molecule attachment to nanoparticles
AR065865A1 (es) 2007-03-30 2009-07-08 Hirofumi Takeuchi Liposoma para la administracion pulmonar para controlar el suministro de la droga
EP2146794B1 (en) 2007-04-12 2016-10-19 Biomet Biologics, LLC Buoy suspension fractionation system
DK2170353T3 (en) 2007-05-18 2015-07-27 Adiutide Pharmaceuticals Gmbh The phosphate-modified oligonucleotide analogs with immunostimulatory activity
AU2008259907B2 (en) 2007-05-30 2014-12-04 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
KR20100050443A (ko) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
CA2731399A1 (en) 2007-07-23 2009-01-29 Aarhus Universitet Nanoparticle-mediated treatment for inflammatory diseases
EP2173912A4 (en) 2007-08-01 2013-03-20 Idera Pharmaceuticals Inc NEW SYNTHETIC AGONISTS OF TLR9
SI2179039T1 (sl) * 2007-08-13 2019-01-31 Zoetis Belgium S.A. Motivi RNA-zaporedja v kontekstu definiranih mednukleotidnih vezi, ki inducirajo specifične imunsko modulacijske profile
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
WO2009088401A2 (en) 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Immunostimulatory combinations of tlr ligands and methods of use
WO2009049208A1 (en) 2007-10-12 2009-04-16 The University Of North Carolina At Chapel Hill Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
EP2058397A1 (de) 2007-11-07 2009-05-13 Mologen AG Multimeres Assemblat zur Immunstimulation
BRPI0820302A2 (pt) 2007-11-09 2015-05-19 Univ Northeastern Nanopartículas semelhantes a micelas de automontagem para liberação sistêmica de gene
US20090148384A1 (en) 2007-12-10 2009-06-11 Fischer Katrin Functionalized, solid polymer nanoparticles comprising epothilones
JP5658568B2 (ja) 2007-12-12 2015-01-28 ユニバーシティ・ヘルス・ネットワーク 高密度リポタンパク質様ペプチド−リン脂質足場（「ｈｐｐｓ」）ナノ粒子
WO2009089115A1 (en) 2008-01-04 2009-07-16 Hormel Foods Corporation Encapsulation of oxidatively unstable compounds
JP2011518116A (ja) 2008-02-21 2011-06-23 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション トール様受容体３拮抗薬としての超小型ｒｎａ
BRPI0910036B8 (pt) 2008-03-25 2021-05-25 Juvaris Biotherapeutics Inc kit compreendendo um primeiro administrador para via intra-venosa de um complexo de lipídio catiônico-dna (cldc) e um segundo administrador de uma vacina
EP2105145A1 (en) 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
US20110151000A1 (en) 2008-04-21 2011-06-23 Schultz William J Nitric oxide-releasing compositions, devices and methods
EP2288336B8 (en) 2008-04-25 2017-03-22 Northwestern University Nanostructures suitable for sequestering cholesterol
CA2723226A1 (en) * 2008-05-02 2009-05-11 Cancer Research Technology Ltd Products and methods for stimulating an immune response
US8063131B2 (en) 2008-06-18 2011-11-22 University Of Washington Nanoparticle-amphipol complexes for nucleic acid intracellular delivery and imaging
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
KR20110044764A (ko) 2008-07-28 2011-04-29 이데라 파마슈티칼즈, 인코포레이티드 안티센스 올리고누클레오티드에 의한 톨-유사 수용체 9 발현의 조절
KR20110044277A (ko) 2008-08-04 2011-04-28 이데라 파마슈티칼즈, 인코포레이티드 안티센스 올리고누클레오티드에 의한 톨-유사 수용체 ３ 발현의 조절
US20100047188A1 (en) 2008-08-04 2010-02-25 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 8 expression by antisense oligonucleotides
EP2328613A1 (en) 2008-08-28 2011-06-08 GlaxoSmithKline Biologicals S.A. Vaccine
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
EP3225621A1 (en) 2008-10-09 2017-10-04 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
HUE028497T2 (en) 2008-10-16 2016-12-28 The Univ Of Saskatchewan Combination adjuvant composition
US20130090457A1 (en) 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
CN106955360A (zh) 2008-11-24 2017-07-18 西北大学 多价rna纳米颗粒组合物
DK2370112T3 (en) * 2008-11-24 2017-07-24 Bonus Cellora Ltd IMPLANTABLE LIPOSOM INHIBITED MATRIX COMPOSITION AND APPLICATIONS THEREOF
ES2572563T3 (es) 2008-12-09 2016-06-01 Coley Pharmaceutical Group, Inc. Oligonucleótidos inmunoestimulantes
US8298765B2 (en) 2009-01-01 2012-10-30 Cornell University Multifunctional nucleic acid nano-structures
KR20110102492A (ko) 2009-01-08 2011-09-16 노오쓰웨스턴 유니버시티 다가 올리고뉴클레오티드 변형된 나노입자 접합체에 의한 박테리아 단백질의 생산 저해 방법
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20120040004A1 (en) 2009-01-28 2012-02-16 Region Midtjylland Treatment of radiation-induced fibrosis
CN102300990A (zh) 2009-01-30 2011-12-28 艾德拉药物股份有限公司 Tlr9的合成激动剂
AR070368A2 (es) 2009-02-12 2010-03-31 Smithkline Beecham Biolog Procedimiento para la preparacion de una composicion de vacuna que comprende un inmunoestimulante un antigeno y una sal metalica y uso de dicha composicion para preparar un medicamento.composicion de vacuna
NZ594995A (en) 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
CA2755245A1 (en) 2009-03-13 2010-09-16 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
EP2419535B1 (en) 2009-04-15 2022-08-17 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
EP2246433A1 (de) 2009-04-30 2010-11-03 Mologen AG Concatemere zur Immunmodulation
WO2010147387A2 (en) 2009-06-18 2010-12-23 Industry Academic Cooperation Foundation, Hallym University Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides as active ingredients
WO2011007961A2 (en) 2009-07-17 2011-01-20 Industry Academic Cooperation Foundation, Hallym University Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes
WO2011017382A2 (en) * 2009-08-03 2011-02-10 The Regents Of The University Of California Nanofibers and morphology shifting micelles
US20120277283A1 (en) 2009-08-04 2012-11-01 Mirkin Chad A Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications
US20120269730A1 (en) 2009-08-07 2012-10-25 Northwestern University Intracellular Delivery of Contrast Agents with Functionalized Nanoparticles
CN102625697A (zh) 2009-09-01 2012-08-01 西北大学 使用经寡核苷酸修饰的纳米颗粒作为载体来递送治疗剂
WO2011028847A1 (en) 2009-09-01 2011-03-10 Northwestern University Polyvalent polynucleotide nanoparticle conjugates as delivery vehicles for a chemotherapeutic agent
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
KR101132626B1 (ko) 2009-10-12 2012-04-02 주식회사 녹십자 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법
US20110111974A1 (en) 2009-10-23 2011-05-12 Northwestern University Short Duplex Probes for Enhanced Target Hybridization
JP5866119B2 (ja) 2009-10-30 2016-02-17 ノースウェスタン ユニバーシティ 鋳型ナノ複合体
WO2011072133A1 (en) 2009-12-09 2011-06-16 William Marsh Rice University Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles
US8933046B2 (en) 2009-12-23 2015-01-13 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Influenza targets
WO2011079290A1 (en) 2009-12-24 2011-06-30 Northwestern University Oligonucleotide specific uptake of nanoconjugates
WO2011091065A2 (en) 2010-01-19 2011-07-28 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
EP2399608B1 (en) 2010-03-05 2020-07-08 Sebastian Fuchs Immunomodulating nanoparticulate composition for use in inhalation therapy
WO2011113054A2 (en) 2010-03-12 2011-09-15 Aurasense Llc Crosslinked polynucleotide structure
SG184127A1 (en) 2010-03-19 2012-10-30 Massachusetts Inst Technology Lipid vesicle compositions and methods of use
EP2555802A1 (en) 2010-04-08 2013-02-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
WO2011136828A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
KR101198715B1 (ko) 2010-05-14 2012-11-13 한국생명공학연구원 핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법
CN105194665A (zh) 2010-05-26 2015-12-30 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
EP2575878B1 (en) 2010-05-28 2018-06-13 Zoetis Belgium S.A. Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
US20130089614A1 (en) 2010-06-14 2013-04-11 Xuefeng Zhang Magnetic Nanoparticles and Uses Thereof
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
CN103003427B (zh) 2010-07-28 2015-08-12 国立大学法人北海道大学 具有佐剂活性的新型核酸及其应用
ES2558106T3 (es) 2010-07-30 2016-02-02 Curevac Ag Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
GB201014026D0 (en) 2010-08-20 2010-10-06 Ucl Business Plc Treatment
WO2012031205A2 (en) 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles
KR20130136983A (ko) 2010-09-24 2013-12-13 말린크로트 엘엘씨 치료 및/또는 진단용 나노담체의 목표화를 위한 압타머 접합체
US20130095039A1 (en) 2010-09-30 2013-04-18 The Board Of Trustees Of The University Of Illinois Nucleic acid-mediated shape control of nanoparticles
AU2011322553B2 (en) * 2010-10-26 2015-07-02 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
EP2640420B1 (en) 2010-11-19 2018-08-15 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
WO2012084991A1 (en) 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
JP5902197B2 (ja) 2011-01-11 2016-04-13 アルニラム・ファーマシューティカルズ・インコーポレーテッド Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
BR112013017947A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores de receptor toll-like
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
ES2822350T3 (es) 2011-04-28 2021-04-30 Platform Brightworks Two Ltd Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas
WO2013009701A2 (en) * 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US9517277B2 (en) 2011-07-15 2016-12-13 University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
EP2548571A1 (en) 2011-07-22 2013-01-23 Institut Curie Compositions having means for targeting at least one antigen to dendritic cells
EP2736537A4 (en) 2011-07-29 2015-04-15 Selecta Biosciences Inc SYNTHETIC NANOTRANSPORTERS FOR THE PRODUCTION OF HUMOROUS AND CYTOTOXIC T-LYMPHOCY (CTL) IMMUNE REACTIONS
AU2012305715A1 (en) 2011-09-11 2014-04-10 Aurasense, Llc Cellular uptake control systems
CA2849259A1 (en) 2011-09-19 2013-03-28 The Johns Hopkins University Cancer immunotherapy
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP3563872A1 (en) 2012-04-05 2019-11-06 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
SI2844282T1 (sl) 2012-05-04 2019-08-30 Pfizer Inc. S prostato povezani antigeni in na cepljenju osnovan imunoterapevtski režim zdravljenja
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
US9931418B2 (en) 2012-08-07 2018-04-03 Northeastern University Compositions for the delivery of RNA and drugs into cells
US9095625B2 (en) 2012-08-31 2015-08-04 University Of Massachusetts Graft-copolymer stabilized metal nanoparticles
US9868955B2 (en) 2012-09-29 2018-01-16 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
US9968673B2 (en) 2013-02-26 2018-05-15 Commissariat á l'ènergie atomique et aux ènergies alternatives Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent
CN103212089B (zh) 2013-04-07 2016-08-24 中国科学院上海应用物理研究所 一种碳纳米材料-免疫刺激序列复合物的制备方法及其应用
WO2014169264A2 (en) 2013-04-11 2014-10-16 The Board Of Trustees Of The University Of Illinois Nanoparticle mediated delivery of sirna
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
WO2014201245A1 (en) 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
CN105658241A (zh) 2013-07-25 2016-06-08 埃克西奎雷股份有限公司 作为免疫调节剂的基于球形核酸的构建体
US20150037374A1 (en) 2013-07-31 2015-02-05 Csl Limited Anti-tumor compositions and uses thereof
KR101465365B1 (ko) 2013-10-15 2014-11-25 성균관대학교산학협력단 리포좀 내 고분자 충진된 다중 기능 복합 입자체 및 이의 제조방법
WO2015077657A2 (en) 2013-11-22 2015-05-28 City Of Hope Stat3 inhibitors and uses thereof
MX2016007287A (es) * 2013-12-03 2017-05-03 Univ Northwestern Particulas liposomales, metodos para elaborarlas y sus usos.
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015120382A1 (en) 2014-02-07 2015-08-13 The Johns Hopkins University Predicting response to epigenetic drug therapy
GB2523187A (en) 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
BR112016019837A2 (pt) 2014-02-28 2017-10-17 Bayer Animal Health Gmbh plasmídeos imunoestimuladores
CA2941633C (en) 2014-03-05 2021-01-12 Orbis Health Solutions Llc Vaccine delivery systems using yeast cell wall particles
AU2015240567A1 (en) 2014-04-03 2016-10-20 Exicure, Inc. Self assembling nucleic acid nanostructures
KR102208588B1 (ko) 2014-04-04 2021-01-28 (주)바이오니아 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
WO2015167616A1 (en) 2014-05-02 2015-11-05 Nitor Therapeutics Guanosine as an immunepotentiator mediated through toll receptors
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
US9919058B2 (en) 2014-07-15 2018-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer
PE20170694A1 (es) 2014-10-06 2017-05-26 Exicure Inc Compuestos anti-tnf
WO2016115320A1 (en) 2015-01-14 2016-07-21 Exicure, Inc. Nucleic acid nanostructructures with core motifs
US20180042848A1 (en) 2015-02-18 2018-02-15 Exicure, Inc. Immuno-regulatory lipid containing spherical nucleic acids
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
EP3322407A4 (en) 2015-07-14 2019-07-10 Exicure, Inc. RELOCATION OF LIPID COMPLEXES IN CELLS INDUCED BY SPINICAL NUCLEIC ACIDS (SNA)
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
US20200297867A1 (en) 2016-02-01 2020-09-24 Exicure, Inc. Surface functionalization of liposomes and liposomal spherical nucleic acids (snas)
US20170240960A1 (en) * 2016-02-24 2017-08-24 Aurasense, Llc Spherical nucleic acids (sna) flare based fluorescence in situ hybridization
WO2017184427A1 (en) 2016-04-19 2017-10-26 Exicure, Inc. Topical administration of therapeutic agents and oligonucleotide formulations
WO2017193081A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Spherical nucleic acid tlr9 agonists
WO2017193084A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Tlr9-targeted spherical nucleic acids having potent antitumor activity
JP7186094B2 (ja) 2016-05-06 2022-12-08 イグジキュア オペレーティング カンパニー インターロイキン１７受容体ｍＲＮＡの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド（ＡＳＯ）を提示するリポソーム系球状核酸（ＳＮＡ）構築物
US11052149B2 (en) 2016-09-19 2021-07-06 The University Of North Carolina At Chapel Hill Methods and compositions for inducing an immune response
US20200248183A1 (en) 2017-04-03 2020-08-06 Subbarao Nallagatla Tlr9-targeted spherical nucleic acids having potent antitumor activity
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2019168558A1 (en) 2018-02-28 2019-09-06 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors
WO2019169203A1 (en) 2018-02-28 2019-09-06 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors
EP3923957A4 (en) 2019-02-12 2022-11-02 Exicure Operating Company COMBINED SPHERICAL NUCLEIC ACID AND CHECKPOINT INHIBITOR FOR ANTITUMORS THERAPY
WO2020219985A1 (en) 2019-04-26 2020-10-29 Exicure, Inc. Administration of spherical nucleic acids for ophthalmological uses

Also Published As

Publication number Publication date
US20170157048A1 (en) 2017-06-08
TR201908550T4 (tr) 2019-07-22
EP3508198A1 (en) 2019-07-10
AU2015269412A1 (en) 2016-12-22
EP3164113A1 (en) 2017-05-10
KR102290205B1 (ko) 2021-08-20
US10434064B2 (en) 2019-10-08
AU2015269412B2 (en) 2020-03-12
US20220257512A1 (en) 2022-08-18
JP6581604B2 (ja) 2019-09-25
US11123294B2 (en) 2021-09-21
KR20170005499A (ko) 2017-01-13
EP3164113B1 (en) 2019-03-27
US20200069587A1 (en) 2020-03-05
CN106535876B (zh) 2020-09-11
WO2015187966A1 (en) 2015-12-10
JP2017524658A (ja) 2017-08-31
CA2953216C (en) 2020-12-22
CN106535876A (zh) 2017-03-22
ES2725948T3 (es) 2019-09-30
CA2953216A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
PL3164113T3 (pl) Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych
IL289934A (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
IL249727A0 (en) Liposomal formulations for the transfer of nucleic acids
EP3587409B8 (en) Biodegradable lipids for delivery of nucleic acids
HK1215119A1 (zh) 治療產品遞送系統和配對方法
EP3177638A4 (en) Targeting peptides and methods of use
HK1253310A1 (zh) 革蘭氏陰性菌外膜囊泡抗原表面展示
EP3099173A4 (en) Therapeutic phages and methods for delivery of nucleic acids for therapeutic uses
ZA201700254B (en) Process for the preparation of 4-alkoxy-3-hydroxypicolinic acids
EP3217992A4 (en) Probiotic therapeutic applications
IL247349A0 (en) Anionic polyplexes for use in nucleic acid transduction
HK1256033A1 (zh) 用於刺激免疫系統的肽
SG11201609757XA (en) Biosynthetic production of acyl amino acids
EP3178491A4 (en) Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition
EP3297619A4 (en) Therapeutic uses of l-4-chlorokynurenine
EP3201322A4 (en) Innate immune system modification for anticancer therapy
IL249500A0 (en) Reno vaccine system of influenza vaccine component
IL250637A0 (en) Targeted release of hydrophilic drugs
AU2014905183A0 (en) Delivery of Surface Care Products
GB202008979D0 (en) Therapeutic product delivery system and method of pairing